Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
Date:12/10/2008

since several batches of product that were manufactured during the latter part of the second quarter were not shipped until the third quarter, when these revenues will be recorded.

Total costs and expenses decreased $1,954,000 to $6,491,000 in the second quarter of FY 2009 from $8,445,000 in the same prior year quarter, a decrease of 23%. The decrease was primarily related to planned reductions in R&D costs associated with Peregrine's preclinical programs. These reductions were implemented to maximize the R&D resources available to advance the company's priority clinical product candidates bavituximab and Cotara(R). R&D expenses were $4,301,000 in the second quarter of FY 2009, compared to $5,100,000 in the second quarter of FY 2008. The decrease in R&D expense was achieved despite an increase in clinical activity during the quarter. SG&A expenses were down $416,000 to $1,527,000 for the second quarter of FY 2009 compared to $1,943,000 for the comparable period in FY 2008, a decrease of 21%. This decrease reflects a reduction in SG&A expenses across the board, reflecting the company's focus on stringent management of all discretionary expense categories.

At October 31, 2008, the company had $8,210,000 in cash and cash equivalents. After the close of the quarter, on December 9, 2008, Peregrine entered into an agreement for a non-convertible term loan with an initial tranche of $5 million that will be funded upon closing, with an option to acquire a second $5 million tranche in the future, upon Peregrine's satisfaction of certain additional conditions.

"This past quarter was highlighted by significant milestones for both our bavituximab cancer and anti-viral programs," said Steven W. King, president and CEO of Peregrine. "For the first time, we reported patient enrollment underway in three bavituximab Phase II cancer trials, along with encouraging updated results from o
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
2. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
5. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
6. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
7. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
8. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
9. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
10. ISTA Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference
11. Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... 2014 "As a nurse, patients always ask ... an inventor from Tamaqua, Pa. "The reason that they cannot ... of their chairs. My invention enables them to check oxygen ... Sensor to make it easier to monitor the contents of ... when the tank is low. It allows changeovers to be ...
(Date:9/20/2014)... September 20, 2014 QueenBeeTickets.com is ready ... star’s tour performances. She will visit many cities in ... until the 16th of April. , Click Here ... Tour tickets at QueenBeeTickets.com. , The star’s fans are ... see their favorite young singer in a live performance. ...
(Date:9/20/2014)... The first federal bellwether trial of a DePuy ... in the U.S. District Court, Northern District of Texas, ... the week opened in the DePuy Pinnacle Hip ... vice president, who discussed the clinical testing performed on ... According to Reuters, the executive stated that the Pinnacle ...
(Date:9/19/2014)... 2014 Nearly 780 Risperdal lawsuits are ... where a meeting took place to discuss the next ... in the court’s mass tort program. Attorneys for the ... week at the Complex Litigation Center in Philadelphia’s City ... proceedings. The Risperdal lawsuits filed against Johnson & Johnson ...
(Date:9/19/2014)... City, KS (PRWEB) September 19, 2014 ... is responding to families in regions of the Philippines being ... , More than 1,060 families evacuated to the nearest ... storm Fung-Wong brought heavy rain and gusty winds to portions ... Friday causing heavy flooding. Some homes filled with more than ...
Breaking Medicine News(10 mins):Health News:Discount Ariana Grande Tickets: QueenBeeTickets.com Delights Fans with Discount Concert Tickets for Ariana Grande’s 2015 Honeymoon Tour 2Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 2Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 3Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 4Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 3Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 4Health News:Double Threat in Philippines Displaces Thousands of Unbound Families 2
... Maureen Salamon HealthDay Reporter , TUESDAY, Aug. ... investigating injectable drugs to treat psoriasis -- an autoimmune ... medications are not linked to higher heart risks. ... information from drug makers impeded their ability to assess ...
... bowel disease (IBD), which affects more than 1 million ... response triggered by environmental factors, such as bacteria, in ... inflammation of the lining of the colon, is one ... IBD is prompted by different cytokines small signaling ...
... Reporter , TUESDAY, Aug. 23 (HealthDay News) -- A test ... are most likely to raise the risk of invasive cervical ... accurate for many women than the Pap test alone, a ... HPV-positive, using the HPV test alone appears to be enough, ...
... are to investigate whether the therapeutic effects of clay ... of anger, anxiety and depression. Academics are teaming ... gallery and local artists for the innovative project that ... offer to young people struggling with mental health problems. ...
... psychology department show that people who use more ... are viewed more negatively than those who use milder ... adults are more negative about using anti-aging methods than ... rapid growth of the anti-aging cosmetic industry, age concealment ...
... drug and mental disorders would benefit greatly from smoking ... be five times more successful at kicking the habit, ... Center has found. Smokers with these comorbid conditions ... have a more difficult time quitting and represent a ...
Cached Medicine News:Health News:Injectable Psoriasis Drugs May Not Hike Heart Risks: Study 2Health News:Injectable Psoriasis Drugs May Not Hike Heart Risks: Study 3Health News:Novel cytokine protects mice from colitis 2Health News:HPV Test Might Be Better Predictor of Cervical Cancer Than Pap Smear 2Health News:HPV Test Might Be Better Predictor of Cervical Cancer Than Pap Smear 3Health News:Modelling emotions: A potential new therapy for disturbed teenagers 2Health News:Modelling emotions: A potential new therapy for disturbed teenagers 3Health News:U of T research shows anti-aging techniques not yet viewed as acceptable 2Health News:Smokers with comorbid conditions need help from their doctor to quit 2Health News:Smokers with comorbid conditions need help from their doctor to quit 3
(Date:9/19/2014)... Sept. 19, 2014  Alere Inc. (NYSE: ... the following statement today in support of President ... "As the global leader in rapid diagnostics for ... national strategy to address the serious threat of antibiotic ... the Administration on initiatives to promote the development of ...
(Date:9/19/2014)... ORLANDO, Fla. , Sept. 19, 2014 /PRNewswire/ ... to grow, with the publication of two papers this ... Otolaryngology – Head and Neck Surgery , ... both objective and subjective measures of sleep disordered breathing, ... for the reduction in obstructive sleep apnea severity and ...
(Date:9/19/2014)... , Sept. 19, 2014  CytRx Corporation (Nasdaq: ... company specializing in oncology, today announced that David ... at BioCentury,s 2014 NewsMakers in the Biotech Industry Conference on ... Time. The conference will take place at the Millennium ... . A live and archived webcast of ...
Breaking Medicine Technology:Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3
... MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today ... conferences in September: Stifel Nicolaus Healthcare Conference Thursday, ... UBS Global Life Sciences Conference Wednesday, September 21, at 9:30 ... of each event will be available on the Investor Relations ...
... Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS, ASX: UNS), today ... presenting at two upcoming investor conferences taking place in New ... will present at the Rodman and Renshaw Annual Global Investment ... On Wednesday, September 14, Mr. Shortall will present at the ...
Cached Medicine Technology:Unilife to Participate in Two Investor Conferences 2
... a sterile, nonpyrogenic, viscoelastic preparation of ... weight fraction of sodium hyaluronate., ,Healon ... dissolved in physiological sodium chloride phosphate ... weight polymer is made up of ...
... DUOVISC Viscoelastic System is designed to ... properties that can be used differently and ... cataract procedure. The choice of the viscoelastic ... differential ability of each to facilitate performance ...
... fiscal year 2004, Biomet plans to ... to the global market, enhancing visualization ... Acumen technology was developed in conjunction ... based in Hollywood, Florida. Procedure-specific software ...
... in awhile, a product comes along that ... in its category. The new StealthStation TREON ... a product. Built on the phenomenal success ... surgical navigation system in the worldthe new ...
Medicine Products: